The indication that LH3 regulates the posttranslational lysine modification of adiponectin makes it a potential candidate for the development of future therapeutic treatments for various metabolic and cardiovascular abnormalities associated with obesity and insulin resistance, which are linked to the dysregulation of adiponectin secretion. Here, ADIPOQ is linked to Insulin resistance.